AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17370488
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of amiodarone
Trial: 11174621
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation 5 mg/d (SG)
Trial: 9753804
Drug: Intramuscular narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular narcotic injections (Group 2, n = 30)
Trial: 8154809
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TS and FNAC
Trial: 3144941
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (15 mg/kg)
Trial: 3144941
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (1 g/m2 body surface area)
Trial: 3144941
Drug: Intramuscular sodium
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular sodium aurothiomalate (up to 100 mg/week)
Trial: 27521574
Drug: Atomoxetine (80-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (80-100 mg/day)
Trial: 27885061
Drug: Alemtuzumab 12
RxNorm normalized name: alemtuzumab 12 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab 12 mg/day (5 days at baseline and 3 days at Month 12)
Trial: 27885061
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta‐1a 44 µg three times/week
Trial: 26422822
Drug: Transdiagnostic cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic cognitive behavior therapy (TD‐CBT)
Trial: 26422822
Drug: Disorder-specific cognitive
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disorder-specific cognitive behavior therapy (DS‐CBT)
Trial: 21753868
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment consisting of daily pelvic floor muscle training with weekly supervision for 2 months.
Trial: 21753868
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after treatment for 2 months.
Trial: 25796337
Drug: Both rHA
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both rHA and HSA formulations
Trial: 8936516
Drug: terbutaline injection
RxNorm normalized name: terbutaline Injection
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: terbutaline injection
Trial: 8936516
Drug: sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile water injection (control)
Trial: 6808622
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (administered via metered dose aerosol at a lower dose than currently used)
Trial: 29678969
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of the EHR to default to a dispense quantity of 10 tablets
Trial: 27906598
Drug: Supplemental O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental O2 with oral dexamethasone 8 mg q8 hours
Trial: 27906598
Drug: Supplemental O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental O2 with sustained release oral nifedipine 20 mg q8 hours
Trial: 24587571
Drug: Zolpidem 3.5
RxNorm normalized name: zolpidem 3.5 mg sublingual tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 3.5 mg (ZST)
Trial: 20307353
Drug: Intervention 1
RxNorm normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention 1 (60 g WG/d for 16 weeks)
Trial: 20307353
Drug: Intervention 2
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention 2 (60 g WG/d for 8 weeks followed by 120 g WG/d for 8 weeks)
Trial: 18559985
Drug: Tertatolol (beta-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertatolol (beta-adrenergic receptor antagonist)
Trial: 18559985
Drug: Phentolamine (alpha-AR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (alpha-AR antagonist)
Trial: 7038977
Drug: Ancrod (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ancrod (daily subcutaneous injections)
Trial: 31480676
Drug: Whey Protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey Protein (WG) 40 g/day
Trial: 31480676
Drug: Hydrolysed Collagen
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrolysed Collagen (CG) 38 g/day
Trial: 26765515
Drug: Feedback group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback group (provided with activity and sleep data during each HD treatment)
Trial: 22803426
Drug: Ligustrazine Injection
RxNorm normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligustrazine Injection (LI) 2 mg/kg given by intravenous dripping 30 min before autologous blood collection
Trial: 22803426
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Ligustrazine Injection)
Trial: 18039195
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination inhalers containing F/S
Trial: 18039195
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or parenteral corticosteroids (7-14 days) and other medications (retrospective group)
Trial: 18039195
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or parenteral corticosteroids (7-14 days) and other medications (prospective group)
Trial: 1417008
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 80 mg/m2 + Carboplatin (CBDCA) 400 mg/m2
Trial: 1417008
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 80 mg/m2 + Carboplatin (CBDCA) 350 mg/m2
Trial: 3857335
Drug: Mandibular repositioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular repositioning treatment
Trial: 3857335
Drug: Flat plane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat plane occlusal splint treatment
Trial: 29861388
Drug: Liraglutide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3.0 mg for 16 weeks
Trial: 19061675
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alpha plus ribavirin (peg‐IFNalpha/RBV) treatment for 48 weeks
Trial: 17333800
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 vaginal tablets
Trial: 9452848
Drug: Intrathecal pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal pethidine (40 mg)
Trial: 9452848
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (2 ml 0.5%)
Trial: 7639022
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous ketamine
Trial: 3286166
Drug: Constant insulin
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant insulin infusion (0.175 mU/kg.min)
Trial: 3286166
Drug: Pulsatile insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile insulin delivery (2.1 mU/kg at 12-min intervals)
Trial: 3286166
Drug: Both constant
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both constant and pulsatile insulin delivery
Trial: 10827333
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive (OC) containing ethinyl estradiol 20 microg and 0.1 mg levonorgestrel
Trial: 10827333
Drug: Lunelle (injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lunelle (injectable contraceptive containing estradiol cypionate 5 mg and medroxyprogesterone acetate 25 mg)
Trial: 1487095
Drug: Linear amplifier
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear amplifier (condition L)
Trial: 2982563
Drug: Low-dose antacid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antacid gel (6 X 12 ml/d; neutralisation capacity 120 mmol)
Trial: 2982563
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g/d)
Trial: 30560740
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment for 6 weeks
Trial: 27209068
Drug: Person-centered progressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Person-centered progressive resistance exercise performed twice a week for 15 weeks
Trial: 15752388
Drug: cAAI-guided propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cAAI-guided propofol infusion (Group G, n = 10)
Trial: 15752388
Drug: cAAI values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cAAI values in Group G
Trial: 12027841
Drug: Sevoflurane titration
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane titration with A‐line auditory guidance (target auditory evoked potential index of 30+/‐5)
Trial: 12027841
Drug: Sevoflurane titration
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane titration clinically (without AEP guidance)
Trial: 10439477
Drug: Hypericum preparation
RxNorm normalized name: Hypericum oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum preparation standardised to 0.17 mg total hypericin per day (114 patients)
Trial: 10439477
Drug: Hypericum preparation
RxNorm normalized name: Hypericum oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum preparation standardised to 0.33 mg total hypericin per day (115 patients)
Trial: 10439477
Drug: Hypericum preparation
RxNorm normalized name: Hypericum oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum preparation standardised to 1 mg total hypericin per day (119 patients)
Trial: 7852667
Drug: Azelastine (0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (0.56 mg/day)
Trial: 2181434
Drug: Tamoxifen (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (exact dosage not specified)
Trial: 2181434
Drug: Placebo (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (exact dosage not specified)
Trial: 322794
Drug: Cholestyramine (doubled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (doubled dose)
Trial: 12636120
Drug: Peroxide control
RxNorm normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroxide control (peroxide gel)
Trial: 12636120
Drug: Light control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light control (placebo gel and light)
Trial: 10992827
Drug: Metamizol (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol (1.2 g)
Trial: 30395050
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake of 1.49 ± 0.44 g·kg·d for oxidation (Ox)
Trial: 30395050
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake of 1.53 ± 0.32 g·kg·d for net protein balance (NB)
Trial: 30395050
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake (0.2-2.9 g·kg·d)
Trial: 27618886
Drug: Topical betuline
RxNorm normalized name: betulin
DrugBank: Betulin (DB16890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betuline gel (TBG)
Trial: 22234041
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement containing n-3 polyunsaturated fatty acids (2 cans/day, 2.02 g eicosapentaenoic acid + 0.92 g docosahexaenoic acid/day)
Trial: 22234041
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement containing n-3 polyunsaturated fatty acids
Trial: 22234041
Drug: Isocaloric control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric control supplement
Trial: 20194829
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (CBGT + phenelzine)
Trial: 17322426
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg b/d)
Trial: 17322426
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg t.d.s)
Trial: 15662518
Drug: Typical antipsychotic
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical antipsychotic drugs
Trial: 15662518
Drug: Drug-free patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free patients
Trial: 11900994
Drug: Lovastatin (10-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (10-60 mg once-daily doses of a controlled-release formulation)
Trial: 9990816
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 500 mg clarithromycin + 2 x 1000 mg amoxicillin + 40 mg pantoprazole/day for 7 days
Trial: 9990816
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 500 mg clarithromycin + 2 x 400 mg ranitidine bismuth citrate/day for 14 days
Trial: 2181859
Drug: 2.2 g
RxNorm normalized name: Vaporizer Safeguard 2.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 g n-3 FAs/d (group 1)
Trial: 2181859
Drug: 1.1 g
RxNorm normalized name: Giazo 1.1 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 g n-3 FAs/d (group 2)
Trial: 30073766
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once daily for 16 weeks
Trial: 8589023
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2) and cisplatin (50 mg/m2)
Trial: 7230259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of self-control and cue extinction procedures
Trial: 29737099
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg voriconazole tablets
Trial: 23071122
Drug: Ramipril (R;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (R; 10 mg daily)
Trial: 23071122
Drug: Telmisartan (T;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (T; 80 mg daily)
Trial: 23071122
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ramipril and Telmisartan (T+R)
Trial: 16896736
Drug: NV (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NV (no treatment)
Trial: 14520020
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (330 ml/day providing 37.0 mg/day lycopene)
Trial: 14520020
Drug: Carrot juice
RxNorm normalized name: carrot juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot juice (330 ml/day providing 27.1 mg/day beta-carotene and 13.1 mg/day alpha-carotene)
Trial: 7567290
Drug: Cefixime (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (7.5 mg/kg orally twice daily for 14 days)
Trial: 7567290
Drug: Ceftriaxone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (50 to 70 mg/kg im once daily for 5 days)
Trial: 7567290
Drug: Aztreonam (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (50 to 70 mg/kg im every 8 hours for 7 days)
Trial: 2026339
Drug: Hypnotic relaxation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic relaxation period
Trial: 31594202
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment applied to trigger points
Trial: 31585944
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 800 mg four times daily for five days (total 16 g)
Trial: 31585944
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 1000 mg three times daily for 10 days (total 30 g)
Trial: 25829811
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg before PCI and for 5 days after PCI
Trial: 25829811
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 mg daily after PCI)
Trial: 16463053
Drug: Verapamil hydrochloride
RxNorm normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil hydrochloride (calcium channel blocker), starting 3 days before SWL and continued for 4 weeks after the procedure
Trial: 16463053
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific medication (control group)
Trial: 15001941
Drug: Desmopressin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (20-40 microg intranasal) with conditioning alarm therapy
Trial: 15001941
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray with conditioning alarm therapy
Trial: 7896541
Drug: Cisplatin 14
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 14 mg/m2 daily and 5-fluorouracil 700 mg/m2 daily for 5 days plus alpha-interferon 1 x 10(6) units/m2 daily for five days (phase I)
Trial: 7896541
Drug: Cisplatin 17
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 17 mg/m2/day, 5-fluorouracil 700 mg/m2/day and alpha-interferon 3 x 10(6) units/m2/day (phase II)
Trial: 28194093
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g whey protein + 2 g amylopectin-chromium complex (WPACr)
Trial: 28194093
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g whey protein (WP)
Trial: 25242569
Drug: 50-μg transdermal
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-μg transdermal estradiol patch
Trial: 24103853
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (LTPP + Fluoxetine)
Trial: 20729000
Drug: Arginine Vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine Vasopressin nasal spray (20 IU)
Trial: 17175311
Drug: 7 x
RxNorm normalized name: TachoSil 3.7 X 1.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 x 10 g IVIG
Trial: 17175311
Drug: 7 x
RxNorm normalized name: TachoSil 3.7 X 1.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 x 10 g IV albumin
Trial: 15041604
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (PCEA; 0.125% ropivacaine plus sufentanil 1 microg/mL at a base rate of 12 mL/h and bolus application of 5 mL/15 min)
Trial: 15041604
Drug: Conventional patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional patient-controlled IV analgesia (PCIA; morphine 3 mg/15 min)
Trial: 11461124
Drug: Sequential antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential antibiotic therapy (switch therapy)
Trial: 9426760
Drug: Tolterodine 1
RxNorm normalized name: tolterodine 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 1 mg and 2 mg